Edwards Lifesciences has reported the publication of new clinical data demonstrating reduced hospital stay and complications associated with the use of FloTrac system for monitoring critical care patients, when compared to standard hemodynamic monitoring.
The randomised, controlled clinical trial of 60 high-risk abdominal surgery patients found that enhanced hemodynamic monitoring with the FloTrac system reduced hospital stay by more than 20% when compared to standard monitoring.
In addition, patients monitored with the FloTrac system experienced 60% fewer complications than the control group. The single-center study was performed at Klinikum Ludwigshafen in Ludwigshafen, Germany and the data were published in the journal Critical Care.
Joachim Boldt, department of anesthesiology and intensive care medicine at Klinikum Ludwigshafen, said: “These new data represent clinical evidence that a hemodynamic monitoring protocol optimized by using the FloTrac system may improve patient outcomes, an end-goal that all critical care clinicians seek. These results are encouraging for patient outcomes, and by reducing hospital stays, there is also potential to lower costs.”
Carlyn Solomon, corporate vice president of Edwards, said: “We strive to provide clarity of patient information for clinicians to enable informed decision-making that leads to optimal outcomes. We are gratified to be building a portfolio of evidence that demonstrates the clinical value of this advanced method of monitoring to enhance the care of the critically ill.”